Type 4 drugs act via unknown mechanisms and include isoniazid (INH), methyldopa, captopril, tricyclic antidepressants (TCAD), diazepam, heroin and cannabis.6,7 Spironolactone is a steroidal antimineralocorticoid and is one of the medications that have been most linked with gynecomastia. Gynecomastia can be typically classified into four grades of increasing severity, from I to IV, ranging from simple areolar protrusion, to breasts with a female appearance. It usually regresses within 18m and is uncommon in males aged 17 and older.8,11 The final peak occurs in older males (particularly in those aged years-old), with a prevalence of 24-65%. Testosterone Replacement Therapy (TRT) can help balance the hormones and shrink the breast tissue. Gynecomastia is common in men over 50 due to declining testosterone levels and increased estrogen activity. Approximately 60-90% of newborn males have transient gynecomastia due to maternal estrogen exposure. All individuals, whether male or female, possess both female hormones (estrogens) and male hormones (androgens). Normally developing pubertal males may be at risk for gynecomastia, which is part of the normal developmental process. True gynecomastia disease results from the growth of the glandular breast tissue, which is present in very small amounts in men. In several studies, prophylactic RT was found to be effective in preventing gynecomastia and mastodynia in patients with prostate cancer.2,11 However, although the high radiation doses may improve pain, they are less effective in reducing the volume of the tissue. In one study of the use of Tmx, 69% of prostate cancer patients in the high-dose bicalutamide (150 mg/day) group had gynecomastia, but this was reduced to only 9% in the group receiving both bicalutamide and Tmx (10-20 mg/day).30,31,32 Tmx must be continued throughout the anti-androgen therapy, since its effects do not persist after it has been discontinued. Anti-estrogens–In recent years, anti-estrogens have been increasingly used to decrease the stimulatory effects of estrogen on the male breast. Dehydrotestosterone (DHT) is a non-aromatizable androgen that has been approved for the treatment of gynecomastia in some countries and was found to be effective in uncontrolled studies.17,18 Danazole is a weak androgen that inhibits the secretion of LH and FSH from the pituitary. But if caused by glandular tissue growth (true gynecomastia) then weight loss won’t get rid of the problem. So if it appears suddenly or persists, seek medical attention as a doctor can rule out any serious condition. Also in some cases, it can be a sign of an underlying medical condition. However, long-standing cases may require medical treatment or surgery. In many cases, gynecomastia in men is reversible, especially if it is caused by temporary factors like medication use or hormonal changes during puberty. However, you should consult a doctor to determine the underlying cause of the condition and get proper guidance on treatment options. Gynecomastia occurs when there is an imbalance between estrogen and androgen levels. Anabolic steroids used for bodybuilding can lead to gynecomastia due to the conversion of excess testosterone into estrogen. But TRT isn’t always the solution and in some cases can make gynecomastia worse if too much testosterone is converted to estrogen. Withdrawing an offending drug or treating an underlying disorder may be sufficient, especially if gynaecomastia is relatively recent. Most primary breast carcinomas in men are ductal, either invasive or non-invasive (ductal carcinoma in situ).16 Papillary histology is more common and lobular histology is rare in men (fig 3). Mammography is about 90% sensitive and 90% specific for malignant compared with benign masses in men.15 Invasive cancers are solid on ultrasonography. Imaging is not necessary if cancer is not suspected. Other important physical findings include adiposity, signs of hyperthyroidism, liver disease, hypogonadism (gynoid body habitus, decreased body hair, small testes consistent with Klinefelter’s syndrome), excessive musculature indicating exogenous androgen administration, or a testicular mass. Gynaecomastia is characterised by proliferation of ductules and loose connective tissue. Increased stress can stimulate the adrenal glands to secrete excess estrogen precursors. After dialysis, patients are free to resume a regular diet and often regain weight. Before dialysis, renal failure patients have restricted diets, can be malnourished and tend to lose weight. Gynecomastia is observed in approximately 50% of hemodialysis patients, primarily due to Leydig cell dysfunction. In addition, SHBG is often increased, leading to increased concentrations of E2. If differentiating between gynecomastia and breast cancer cannot be achieved using physical and imaging findings, a percutaneous biopsy should be taken. Heterogeneous inversion or polymorphism of the p450 aromatase gene leads to increased aromatase activity in peripheral tissues, resulting in elevated estrogen levels. Gynecomastia in patients with cirrhosis or liver disease is caused by increased production of androstenedione (A) from adrenal glands, increased aromatization of A to E1, increased conversion of E1 to E2, decreased clearance of adrenal androgens from the liver and increased SHBG, which leads to a decrease in free T levels. Medications have been reported to cause up to 25% of cases of gynecomastia and they can be categorized by their hormone-like action.6,10 Type 1 medications act like estrogens and include diethylstilbestrol (DEB), oral contraceptives, phytoestrogens, digitalis and estrogen-containing cosmetics. During puberty, hormonal fluctuations can lead to temporary breast enlargement because of breast tissue. Stage 1 gynecomastia is the initial phase of breast development, where there is a small enlargement of breast tissue with minimal swelling. The definition of gynecomastia is the presence of breast tissue greater than 0.5 cm in diameter in a male. See your doctor right away if you have any of these symptoms that may be signs of breast cancer in males. In cases of hyperthyroidism, breast enlargement is usually resolved after restoration of the euthyroid state. It is frequently caused by the direct stimulation of peripheral aromatase, candy96.fun because elevated LH levels contribute to increased E2 levels and T production from Leydig cells. Although treatment with gonadotropins can lead to secondary hypogonadism, they do not directly cause gynecomastia. Finally, tumors can lead to gynecomastia due to increased aromatase activity in the tumor itself. It increases the aromatization of T to E2, reduces T production in the testis, displaces T from Sex-hormone binding globuline (SHBG) and increases the metabolic clearance of T.
